Mumbai: Global pharma major Lupin Limited has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for ...

Lupin's Pithampur manufacturing unit produces both APIs (Active Pharmaceutical Ingredients) and finished products ...

Lupin’s Pithampur Unit-1 facility gets EIR from US FDA with VAI classification: Our Bureau, Mumbai Thursday, January 9, 2025, 12:30 Hrs [IST] Global pharma major Lupin Limited ( ...

The Food and Drug Administration has given Lupin a tentative nod for two new generics. The first medication is loteprednol etabonate ophthalmic gel, 0.38%, which is a generic of Bausch & Lomb’s ...

of Takeda Pharmaceuticals U.S.A., Inc. The product will be manufactured at Lupin’s Pithampur facility in India. USFDA grants tentative approval to Lupin’s generic formulation for type 2 ...

Pharma sector grew 8% in FY24: Report The product will be manufactured at Lupin’s Pithampur facility in India. Prednisolone Acetate Ophthalmic Suspension USP, 1% is indicated for the treatment ...

30 Sep 2024 The Mumbai-based pharmaceutical company announced that the US FDA conducted an inspection of Lupin’s Pithampur Unit-1 API and finished product manufacturing facility from September ...

Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly, in an effort to enhance its diabetes portfolio, the company said in an exchange filing on December 30. Lupin had been ...

The Indian pharmaceutical industry will likely grow ... thus delivering higher operating leverage benefits. • Lupin: Motilal Oswal said Lupin has shown earnings turnaround, driven by the ...